Please login to the form below

Not currently logged in
Email:
Password:

Prevail Therapeutics adds to its board of directors

Francois Nader joins the biotech

Francois NaderPrevail Therapeutics, a biotechnology company focused on the development of gene therapies for patients with neurodegenerative diseases, has strengthened its board of directors with the addition of Francois Nader.

From 2008-2015 Nader was president and chief executive officer of NPS Pharma, until Shire acquired the company for $5.2bn.

Nader said: “I am honoured to join the board of Prevail Therapeutics.

“The Prevail team has already made great progress in developing potential treatments for Parkinson’s disease and other neurodegenerative diseases, and I look forward to partnering with the team to help accelerate important therapeutic advances for patients with these devastating illnesses.”

Before his time at NPS, Nader was a venture partner at Care Capital and he also previously served on the North America leadership team of Aventis and its predecessor companies, holding a number of executive positions including senior vice president of integrated healthcare markets.

Commenting on the appointments, Asa Abeliovich, founder and chief executive officer at Prevail, said: “Francois’ leadership and proven track record in building and operating biotech companies will be invaluable as we advance our pipeline of gene therapy programmes toward the clinic.”

31st May 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...